PVI
TBPH icon

Pura Vida Investments’s Theravance Biopharma TBPH Stock Holding History

Pura Vida Investments’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100,000
Closed -$740K – 306
2021
Q3 		$740K Buy
100,000
+51,234
+105% +$573K 0.02% 237
2021
Q2 		$708K Buy
+48,766
New +$916K 0.02% 194

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Pura Vida Investments's TBPH Position: Q4 2021 in Review

Pura Vida Investments sold out of Theravance Biopharma (TBPH) in Q4 2021, closing a stake of 100,000 shares — an estimated $740K sold.

Pura Vida Investments first reported a position in TBPH in Q2 2021 and held it in 2 quarters. The position peaked at $740K in Q3 2021. 116 funds tracked by Wall St. Rank hold TBPH as of Q4 2021.

  • Pura Vida Investments reported no remaining Theravance Biopharma position as of Q4 2021 after selling out during the quarter.
  • Pura Vida Investments sold 100,000 Theravance Biopharma shares in Q4 2021, an estimated $740K.
  • Pura Vida Investments first reported a position in Theravance Biopharma in Q2 2021 and held it in 2 quarters.
  • Pura Vida Investments's Theravance Biopharma position peaked at $740K in Q3 2021.
  • 116 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2021.

Based on Pura Vida Investments's 13F filing for Q4 2021, filed 14 Feb 2022.